Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma
- MeSH Terms
ovarian neoplasms, ovary tumour, ovary, fallopian tube, primary peritoneal, cancer, neoplasm, adenocarcinoma, carcinoma, malignant, tumour, metastases, drug therapy, antineoplastic agent, chemotherapy, adjuvant chemotherapy, consolidation chemotherapy, antineoplastic combined chemotherapy protocols, molecular targeted therapy, systemic, biologic, targeted, immunotherapy, hormone, maintenance, therapy, treatment, adriamycin, carboplatin, cisplatin, platinum, platamin, neoplatin, cismaplat, cis-diamminedichloroplatinum, cisdiamminedichloroplatinum, cyclophosphamide, doxorubicin, epirubicin, gemcitabine, irinotecan, isosfamide, paclitaxel, taxane, etoposide, platinum, MEK inhibitor, PD-325901, selumetinib, AZD6244, PD184352, CI-1040, PD035901, TAK-733, binimetinib, MEK162, ARRY-162, ARRY-438162, trametinib, GSK1120212, mekinist, cobimetinib, cotellic, XL518, GDC-0973, poly(ADP-ribose) polymerase inhibitors, olaparib, AZD2281, lynparza, AZD221, veliparib, ABT888, talazoparib, BMN673, nintedanib, iniparib, oregovomab, abagovomab, CA-125, MUC 16, pazopanib, niraparib, MK4827, rucaparib, PF-01367338, AG014699, rapamune, rapamycin, sirolimus, I2190A, AY 22989, cediranib, recentin, AZD2171, antibodies, monoclonal, humanized, bevacizumab, avastin, mTOR inhibitor, temsirolimus, CCI 779, torisel, everolimus, afinitor, certican, RAD001, SDZ-RAD, deforolimus, ridaforolimus, MK8669, AP23573, BRAF inhibitor, PLX8394, vemurafenib, RG7204, R05185426, PLX4032 or PLX-4032, zelboraf, dabrafenib, tafinlar, GSK2118436, tumour-infiltrating lymphocyte therapy, cytokines, IL-2, interferon, IFN-alpha, immune checkpoint inhibitor, thalidomide, sedoval, thalomid, revlimid, lenalidomide, CC5013, S-3APG, pomalidomide, pomalyst, imnovid, CC-4047, bacille calmette-guerin, tamoxifen, tomaxithen, zitazonium, soltamox, novaldex, nolvadex, ICI47699, ICI46474, fareston, fulvestrant, faslodex, ZM 182780, ICI182780, letrozole, femara, CGS-20267, anastrozole, arimidex, ICI D1033, ZD-1033, examestane, aromasin, FCE-24304, cystorelin, dirigestran, factrel, GnRH, gonadoliberin, luliberin, gonadotropin-releasing hormone, kryptocur, LFRH, luteinizing hormone-releasing hormone, angiogenesis inhibitor, aromatase inhibitor, topotecan, hycamtamine, NSC-609699, SKF104864A, oxaliplatin, eloxatin, docetaxol, taxotere, RP-56976, trabectedin, ecteinascidin, yondelis, ET-743, NSC 684766
- Guideline Contact
- Raymond Poon; pebconc@mcmaster.ca
- Keywords
- ovarian neoplasms, ovary tumour, fallopian tube, primary peritoneal, drug therapy, antineoplastic combined chemotherapy protocols
- Date for Review
- In Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario), we have an annual review process for each guideline after it is completed. Guidelines are reviewed every fall after they are older than 1 year.
- Publication Date
- 2021-01-27
- Date of Last Evidence Search
- Oct-20
- Methods Applied
- Systematic review-based, Externally reviewed, Evidence quality assessment, GRADE approach
- Publication Scope
- Guidelines
- treatment
- Countries of Application
- Canada
- Guideline Publication Status
- Published
- Languages
- English
- Authors
- PEBC (Program in evidenced-based care)
- Publication Year
- 2021